SCHEMBL12529979

SCHEMBL12529979

Cc1cc(C(=O)Nc2ccc(N3CCC(N(C)C)C3)cc2)c(C)n1Cc1cccs1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 5/20 0.62
▸ NPC1 O15118 4/20 0.62
▸ MAPT P10636 2/20 0.62
▸ ALDH1A1 P00352 1/20 0.61
▸ L3MBTL1 Q9Y468 1/20 0.61
▸ MCHR1 Q99705 13/20 0.57
▸ LMNA P02545 2/20 0.49
▸ TP53 P04637 2/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ NR2F2 P24468 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ KLKB1 P03952 1/20 0.47
▸ KLK1 P06870 1/20 0.47
▸ HRH3 Q9Y5N1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12529962 0.85 MCHR1 (0.51) RAB9ANPC1MAPTMCHR1MEN1
SCHEMBL12530196 0.78 MCHR1 (0.63) RAB9AMAPTALDH1A1MCHR1LMNA
SCHEMBL4114205 0.78 RAB9A (0.81) RAB9ANPC1MAPTALDH1A1L3MBTL1
SCHEMBL12530874 0.78 MCHR1 (0.72) RAB9ANPC1MAPTMCHR1SMN1; SMN2
SCHEMBL13558284 0.75 MCHR1 (0.41) RAB9ANPC1MAPTALDH1A1MCHR1
SCHEMBL12529944 0.74 MCHR1 (0.79) RAB9ANPC1MAPTALDH1A1MCHR1
SCHEMBL12530228 0.72 MCHR1 (0.67) MAPTALDH1A1L3MBTL1MCHR1MEN1
SCHEMBL12530936 0.71 MCHR1 (0.76) RAB9ANPC1MAPTALDH1A1L3MBTL1
SCHEMBL12547879 0.71 MCHR1 (0.87) RAB9ANPC1MAPTMCHR1TP53
SCHEMBL12530893 0.70 MCHR1 (0.78) RAB9ANPC1MAPTALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968550-B2 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2011-06-28 — — US disclosed
US-7968550-B2 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2011-06-28 — — US disclosed
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-09-06 — — US disclosed
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-09-06 — — US disclosed
US-7223788-B2 therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-29 — — US disclosed
US-7223788-B2 therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments CYP11B2, CYP11B1, NQO1 RAB9A 4386/4885NPC1 1718/4885MAPT 4800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback